Thursday May 15, 07:57 AM
Prostrakan says first 4 months revenues up 38 pct; strong euro adds 8 percent
LONDON (Thomson Financial) - ProStrakan Plc., the Scotland-based specialty pharmaceutical company, said its product revenues in the first four months of the year increased by 38 percent, with the strong euro contributing 8 percent.
Trading in the period had been at the 'upper end of management expectations', with pan-European growth rates in its Tostran, Rectogesic, Xomolix products of 75 percent, with currency tailwinds accounting for 16 percent of this total, the company said in a trading statement.
Dr Wilson Totten, ProStrakans Chief Executive, said: 'ProStrakan has made an excellent start to the year in terms of product sales in Europe and we have made solid progress towards establishing our business in the US, subject to FDA approval of Sancuso, which is set to be a major inflection point for the business.'
The company will announce its interim results on Aug. 21.
|
|
|
Send Article by Email
